Mer­ck flesh­es out Keytru­da win in first-line cer­vi­cal can­cer, adding more fire­pow­er to its ear­ly can­cer push

Mer­ck has worked hard to bring its I/O block­buster Keytru­da in­to ear­li­er and ear­li­er lines of ther­a­py, and now the won­der drug ap­pears poised to make a quick en­try in­to ear­ly ad­vanced cer­vi­cal can­cer.

A com­bi­na­tion of Keytru­da and chemother­a­py with or with­out Roche’s Avastin cut the risk of death by 33% over chemo with or with­out Avastin (p=<0.001) in first-line pa­tients with per­sis­tent, re­cur­rent or metasta­t­ic cer­vi­cal can­cer, ac­cord­ing to full da­ta from the Phase III KEYNOTE-826 study pre­sent­ed Sat­ur­day at #ES­MO21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER